Current Report Filing (8-k)
October 27 2016 - 08:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October
27, 2016
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-31812
|
|
58-2301143
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
210 Main Street West
Baudette, Minnesota
|
|
56623
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(218) 634-3500
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
|
Results of Operations and Financial Condition.
|
On
October 27, 2016, ANI Pharmaceuticals, Inc. (“ANI,” “we,” or “us”) issued a press release
announcing that we will release our third quarter 2016 financial results on Thursday, November 3, 2016, before the opening of
the U.S. financial markets. We will host a conference call with the investment community at 10:30am, Eastern Time on November
3, 2016. A copy of the press release is furnished as Exhibit 99.1 to this report.
In accordance with General Instruction B.2.
of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to
be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01
|
|
Financial Statements and Exhibits.
|
No.
|
|
Description
|
|
|
|
99.1
|
|
Press release, dated October 27, 2016, issued by ANI
|
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANI PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Stephen P. Carey
|
|
|
|
Stephen P. Carey
|
|
|
|
Vice President, Finance and Chief Financial Officer
|
|
Dated: October 27, 2016
|
|
|
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Feb 2024 to Mar 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Mar 2023 to Mar 2024